Home » News » Industry Specific Issues

Industry Specific Issues

Neuren Pharmaceuticals becomes another Australian Biotech Success Story after US FDA Approves Treatment for Rett Syndrome

March 16th, 2023

Victorian based Neuren Pharmaceuticals’ North American partner, Acadia Pharmaceuticals, has received news this week that its treatment for Rett syndrome was approved by the US Food and Drug Administration. Neuren Pharmaceuticals and Acadia Pharmaceuticals had previously entered an exclusive licence in 2018 to develop and commercialise trofinetide for the treatment of Rett syndrome and other indications. Trofinetide, to be sold under the brand name DAYBUE, is now the first drug to be approved for the treatment of the neurodevelopmental disorder […]

Read More

‘Pick a policy and stick to it’: CSL’s CEO calls for stability on innovation incentives.

February 16th, 2023

CSL is one of Australia’s greatest business and technical success stories and its shares have provided one of the best returns on the ASX among listed companies over the past decade. CSL has also been a very strong advocate of the R&D Tax Incentive and lobbied for maintenance of a strong and stable incentive to encourage local investment in R&D. In an article published in The Australian Financial Review, Paul Perreault, the CEO of CSL, says a bipartisan approach is needed to innovation […]

Read More

Upcoming Senate Debate Over Reconstruction/Manufacturing fund

February 13th, 2023

Leading up to the 2022 federal election, the (then) Opposition Leader Anthony Albanese pledged in early 2022 that he would use Labor’s proposed $15 billion National Reconstruction Fund to make medical technology and local manufacturing investments a top priority. Labor went on to win the election, and are now looking at legislative measures to enact the fund. The National Reconstruction Fund proposes a financing vehicle to specifically drive investment in projects seeking to build prosperity across the country, providing loans, […]

Read More

AFR Article on how CSL priced the world’s most expensive drug

December 8th, 2022

CSL is one of Australia’s greatest business and technical success stories and its shares have provided one of the best returns on the ASX among listed companies over the past decade. CSL has also been a very strong advocate of the R&D Tax Incentive and lobbied for maintenance of a strong and stable incentive to encourage local investment in R&D. A recent article in the Australian Financial review has detailed the process around receipt of US regulatory approval for the […]

Read More

Categories

Archives